Skip to main content

Table 3 Comparison of insulin sensitivity and islet β-cell function

From: Effects of dapagliflozin on serum and urinary uric acid levels in patients with type 2 diabetes: a prospective pilot trial

 

Control

Dapagliflozin 10 mg

P-value

 

Before

After

Con vs Bef

Bef vs Aft

Stumvoll 1st phase index

1342.43 ± 585.89

− 1032.85 ± 1017.65

−  963.63 ± 928.78

 < 0.001

0.775

Stumvoll 2nd phase index

367.02 ± 164.83

− 150.13 ± 223.52

− 144.11 ± 271.71

0.001

0.920

HOMA-β

115.06 ± 50.61

56.02 ± 26.08

59.85 ± 32.77

0.019

0.428

HOMA-IR

2.27 ± 1.24

4.52 ± 2.27

3.78 ± 1.59

0.044

0.624

QUICKI

0.35 ± 0.023

0.31 ± 0.02

0.32 ± 0.02

0.019

0.381

ISIstumvoll

0.078 ± 0.038

0.009 ± 0.017

0.027 ± 0.014

0.001

0.060

ISIMatsuda

119.35 ± 79.74

54.45 ± 25.11

76.95 ± 54.69

0.097

0.093

AUCGlu/Ins

0.20 ± 0.17

0.55 ± 0.49

1.00 ± 1.53

0.446

0.327

AUCIns

212.26 ± 175.00

145.76 ± 94.78

107.83 ± 66.60

0.402

0.069

  1. Con, control; Bef, before; Aft, after; AUCGlu, area under the curve of glucose; AUCIns, area under the curve of insulin; HOMA-IR, homeostasis model assessment of insulin resistance; HOMA-β, homeostasis model assessment of β-cell function; QUICKI, quantitative insulin sensitivity check index; ISIstumvoll, insulin sensitivity index proposed by Stumvoll et al.; ISIMatsuda, insulin sensitivity index proposed by Matsuda et al.; 1st, first; 2nd, second
Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us